Quick View: J&J Boosts Its Multiple Myeloma Portfolio With Positive Clinical Trial Results
Pharmaceuticals / United States / Thu 14 Dec, 2023
The Latest: During the American Society of Haematology (ASH) annual meeting, which took place from December –9-12 2023 in California, Johnson and Johnson (J&J) announced positive data from the Perseus Phase III clinical trial. The study, which evaluated Darzalex Faspro (daratumumab and hyaluronidase) among stem cell transplant-eligible patients